FCGRT and myasthenia gravis: In the era of new biological drugs for MG such as complement-inhibitor monoclonal antibodies (eculizumab, ravulizumab, zilucoplan) and Fc-Rn antagonists (efgartigimod and rozanolixizumab), which are already approved in Europe and in the US [17], and others which are in development, such as baclizumab, inebilizumab, and nipocalimab, azathioprine has still an important role as a disease modifier allowing clinicians to use lower doses of corticosteroids.